Drug-Free Management Tools Provide Alternatives to Opioids in Kidney Cancer

Video

An expert from University Hospitals touches on pain management guidelines that highlight moderate evidence in support of acupuncture, reflexology, and acupressure and massage as tools to manage general pain in patients with cancer.

During Kidney Cancer Awareness Month 2023, Santosh Rao, MD, spoke with CancerNetwork® about evidence from the “Integrative Medicine for Pain Management in Oncology” guidelines from the Society for Integrative Oncology (SIO) and the American Society for Clinical Oncology (ASCO) concerning the efficacy of integrative medicine for patients with solid tumors such as kidney cancer.

Although there was only moderate evidence supporting techniques such as acupuncture and reflexology in the management of general cancer pain and musculoskeletal pain, Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the SIO, stated that these integrative strategies could be a safe alternative for managing pain compared with opioids.

Transcript:

I’ll go over the pain guidelines; it was pretty conservative. Although we may expand these guidelines in the future or the evidence might be more robust, it was really a statement of where we’re at right now. For general cancer pain, there was moderate evidence for the use of acupuncture, reflexology, or acupressure and massage. There was weak evidence for things like yoga and guided imagery.

For neuropathy, there was weak evidence for acupuncture, reflexology, or acupressure. For procedural pain, hypnosis had moderate evidence. For pain during palliative care, massage had moderate evidence. For surgical pain, acupuncture and music therapy had weak evidence.

You contrast [the guidelines] with the fact that these [therapies] are extremely safe. My interest in this kind of approach is that the contrast to using these modalities is to usually use opioids, which have lots of potential [adverse] effects. If you can potentially reduce opioid use with all their [adverse] effects, even if it’s just limiting the amount of opioid use, then that’s a win. You’re not going to get [adverse] effects from music therapy or massage, for example. And we have guidelines around that; it’s important for people to be educated on the safety guidelines when we use these things. That has been really useful.

Reference

Mao JJ, Ismaila N, Bao T, et al. Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 2022;40(34):3998-4024. doi:10.1200/JCO.22.01357

Recent Videos
Ruxolitinib, currently approved for as treatment for patients with myelofibrosis and polycythemia vera, is currently undergoing evaluation in myeloma studies.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, provides advice for upcoming surgeons starting out in the colorectal cancer field.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed how robot-assisted surgery for colorectal cancers has evolved over the past 20 years.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
Related Content